New facility in Frederick, Colorado, to produce high-quality molecules
with the potential to treat cancer and other diseases
SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent
Technologies Inc. (NYSE: A) today announced the opening of a
production facility in Colorado that more than doubles its capacity to
develop and manufacture “oligos,” which are short DNA and RNA molecules
that customers use to produce nucleic acid-based therapeutics.
Agilent expects the demand for therapeutic oligo manufacturing to grow
near 10% each year through 2025, to over $750 million by 2025. This
facility will enable Agilent to meet this growing demand and to continue
being a partner of choice to pharmaceutical and biotech companies.
Shipments to customers from this new site are expected by year-end.
The new state-of-the-art facility is in Frederick, about 30 miles north
of Denver. It produces oligonucleotide (“oligo”) active pharmaceutical
ingredients, which hold the potential to treat cancer, rare and
infectious diseases, cardiovascular indications, and other disorders.
“Our customers are developing innovative therapies that can lead to
truly life-changing outcomes for patients,” said Brian Carothers, vice
president of Agilent’s Nucleic Acid Solutions Division. “As a leading
oligo manufacturer for over 20 years, Agilent is uniquely qualified to
support this critical and growing industry. Our Frederick facility
ensures we will keep up with demand while continuing to deliver a
premium customer service.”
“We’re committed to Frederick and the state of Colorado,” added
Carothers. “Agilent has already brought 100 high-paying jobs to
Frederick. Depending on customer demand, the site can further expand its
manufacturing capacity in the coming years.”
The $185 million facility in Frederick covers 135,000 square feet. It
also expands Agilent’s presence in Colorado, where the company has had
an oligo manufacturing site in nearby Boulder since 2006. Both sites are
current Good Manufacturing Practices (cGMP) facilities, as designated by
the U.S. Food and Drug Administration.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences,
diagnostics, and applied chemical markets. With more than 50 years of
insight and innovation, Agilent instruments, software, services,
solutions, and people provide trusted answers to customers’ most
challenging questions. The company generated revenues of $4.91 billion
in fiscal 2018 and employs 15,550 people worldwide. Information about
Agilent is available at www.agilent.com.
To receive the latest Agilent news, subscribe to our Newsroom.
Follow Agilent on LinkedIn, Twitter,
and Facebook.
Contacts
Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com